Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 5;17(1):823.
doi: 10.1186/s12885-017-3842-z.

Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis

Sonia Blanco-Prieto  1 , Leticia Barcia-Castro  1 , María Páez de la Cadena  1 , Francisco Javier Rodríguez-Berrocal  1 , Lorena Vázquez-Iglesias  1 , María Isabel Botana-Rial  2 , Alberto Fernández-Villar  2 , Loretta De Chiara  3
Affiliations

Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis

Sonia Blanco-Prieto et al. BMC Cancer. .

Abstract

Background: The need for novel biomarkers that could aid in non-small cell lung cancer (NSCLC) detection, together with the relevance of Matrix Metalloproteases (MMPs) -1, -2, -7, -9 and -10 in lung tumorigenesis, prompted us to assess the diagnostic usefulness of these MMPs and the Tissue Inhibitor of Metalloproteinase (TIMP) -1 in NSCLC patients.

Methods: Markers were evaluated in an initial study cohort (19 NSCLC cases and 19 healthy controls). Those that better performed were analyzed in a larger sample including patients with benign lung diseases. Serum MMPs and TIMP-1 were determined by multiplexed immunoassays. Logistic regression was employed for multivariate analysis of biomarker combinations.

Results: MMPs and TIMP-1 were elevated in the serum of NSCLC patients compared to healthy controls. MMP-1, -7 and -9 performed at best and were further evaluated in the sample including benign pathologies, corroborating the superiority of MMP-9 in NSCLC discrimination, also at early-stage NSCLC. The optimal diagnostic value was obtained with the model including MMP-9, gender, age and smoking history, that demonstrated an AUC of 0.787, 85.54% sensitivity and 64.89% specificity.

Conclusion: Our results suggest that MMP-9 is a potential biomarker for NSCLC diagnosis and its combined measurement with other biomarkers could improve NSCLC detection.

Keywords: Diagnosis; Matrix metalloproteases; Non-small cell lung cancer; Serum biomarkers.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was conducted in compliance with the clinical-ethical practices of the Spanish Government and the Helsinki Declaration, and Galician Ethical Committee for Clinical Research approved the protocol. Written informed consent from each patient was obtained.

Consent for publication

Not required.

Competing interests

The authors declare that they have no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013; doi:10.1378/chest.12-2353. - PubMed
    1. Francisci S, Minicozzi P, Pierannunzio D, Ardanaz E, Eberle A, Grimsrud TK, et al. Survival patterns in lung and pleural cancer in Europe 1999-2007: results from the EUROCARE-5 study. Eur J Cancer. 2015; doi:10.1016/j.ejca.2015.07.033. - PubMed
    1. Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013; 10.1002/jso.23382. - PubMed
    1. I H CJY. Lung cancer biomarkers. Adv Clin Chem. 2015; doi:10.1016/bs.acc.2015.07.003. - PubMed
    1. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; doi:10.1038/nrc745. - PubMed

Substances